GLP-1 'month update' videos: what the science says vs. the hype

What did @shanna_beth actually say?

She started liraglutide (Saxenda) one month ago, lost 26.8 pounds in that first month, and is now doing her second injection. She described early nausea as "horrible," said constipation is ongoing, and shared that overeating on liraglutide, even one dinner roll, made her too full to finish a meal. She credited her boyfriend's support as essential to sticking with treatment.

She didn't claim liraglutide cures anything, didn't cite doses, and didn't make outlandish health claims. The video is a personal progress update, not a medical tutorial. That framing matters when evaluating what she got right and wrong.

Does the science back this up?

Partially. The side effects she described, nausea, vomiting, and constipation, are well-documented. The weight loss number, however, is unusually high for one month on liraglutide specifically and deserves scrutiny.

The SCALE Obesity trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that liraglutide 3.0 mg produced an average weight loss of about 8% of body weight over 56 weeks in people without diabetes. That's a slow, cumulative result. Losing 26.8 pounds in a single month would require an extraordinary caloric deficit, especially given that she described barely eating due to nausea and vomiting. It's plausible that a significant portion of that early loss is water weight, glycogen depletion, or loss of stool weight from reduced food intake, not fat mass. Early rapid losses on GLP-1 medications are documented, but 26 pounds in 30 days on liraglutide specifically is at the high end of what the literature would predict.

Her observation about early nausea improving over time also matches the data. Mehta et al. (2017, Obesity Reviews) confirmed that GI side effects on liraglutide peak early and tend to subside with dose titration.

What did they get right or wrong?

She got the side effect profile right. Nausea, vomiting, and constipation are the three most commonly reported adverse effects of liraglutide in clinical trials, and her description of them tracks with what patients actually experience.

She also correctly identified overeating as a risk. GLP-1 receptor agonists delay gastric emptying and suppress appetite, which means overeating doesn't just cause discomfort, it can trigger significant nausea and vomiting. Her Texas Roadhouse story is a real-world illustration of what clinicians call "portion dysregulation" during early treatment.

What she got wrong, or at least incomplete, is the nutrient loss framing. She said she felt she "lost a lot of nutrients" from vomiting. This isn't technically inaccurate as a concern, but it's vague enough to be misleading. Prolonged vomiting on GLP-1 drugs can contribute to electrolyte imbalances, particularly low potassium and magnesium. Simply "drinking water" and staying "caught up with nutrients" is a reasonable instinct but doesn't address the specific deficiencies worth monitoring. Patients on these medications who vomit frequently should be talking to their prescribers about lab monitoring, not just hydrating more.

The 26.8-pound claim is almost certainly real to her scale, but presenting it as a clean "26 pounds of fat gone" is misleading by omission.

What should you actually know?

Liraglutide (Saxenda) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It works differently from semaglutide and tirzepatide in both mechanism and magnitude of effect. Average weight loss in trials is more modest than what many influencers report.

Early dramatic weight loss on any GLP-1 medication often includes fluid shifts and reduced gut contents, not just fat loss. This doesn't mean it isn't working. It means the number on the scale in week four is not the number that reflects your long-term trajectory.

If you're experiencing frequent vomiting on liraglutide, contact your prescriber. It may indicate you're titrating too fast, or it may warrant a temporary dose hold. Managing these side effects proactively affects both your quality of life and your ability to stay on treatment long enough to see real metabolic results.

Her point about support systems is genuinely underrated in clinical conversations. Adherence data on GLP-1 medications is sobering. A 2023 analysis by Wharton et al. in Obesity found that a significant percentage of patients discontinue within the first year. Social support is one of the factors associated with better retention.